Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

Issaka Sagara 1 Abdoul Habib Beavogui 2 Issaka Zongo Issiaka Soulama 3 Isabelle Borghini-Fuhrer Bakary Fofana 4 Aliou Traore Nouhoum Diallo Hamadoun Diakite Amadou Togo 5 Sekou Koumare Mohamed Keita Daouda Camara Anyirékun Somé Aboubacar Coulibaly Oumar Traoré 6 Souleymane Dama 7 Siaka Goïta 8 Moussa Djimde 7 Amadou Bamadio 7 Niawanlou Dara 7 Hamma Maiga 7 Bouran Sidibe Francois Dao Moctar Coulibaly Mohamed Lamine Alhousseini 7 Hamidou Niangaly 9 Boubou Sangare Modibo Diarra Samba Coumare Moïse Kabore San Maurice Ouattara Aissata Barry Désiré Kargougou Amidou Diarra 3 Noelie Henry Harouna Soré Edith Bougouma 3 Ismaila Thera yves Compaore Colin Sutherland 10 Malick Minkael Sylla Frederic Nikiema Mamadou Saliou Diallo Alassane Dicko 1 Stéphane Picot 11 Steffen Borrmann 12 Stephan Duparc Robert Miller 13 Ogobara Doumbo 7 Jangsik Shin José Pedro Gil 14 Anders Bjorkman 15 Jean-Bosco Ouédraogo 16 Sodiomon B Sirima 3 Abdoulaye Djimde 17 
Document type :
Journal articles
Complete list of metadata

https://hal-udl.archives-ouvertes.fr/hal-02136477
Contributor : UMR5246 ICBMS Connect in order to contact the contributor
Submitted on : Wednesday, May 22, 2019 - 10:26:09 AM
Last modification on : Saturday, June 25, 2022 - 10:09:33 AM

Links full text

Identifiers

Citation

Issaka Sagara, Abdoul Habib Beavogui, Issaka Zongo, Issiaka Soulama, Isabelle Borghini-Fuhrer, et al.. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet, Elsevier, 2018, 391 (10128), pp.1378-1390. ⟨10.1016/S0140-6736(18)30291-5⟩. ⟨hal-02136477⟩

Share

Metrics

Record views

37